Business Context and Reporting Period
This Form 8-K was filed by Enochian Biosciences, Inc. (trading symbol: ENOB) on July 20, 2020. The filing reports a corporate event regarding a securities offering rather than a standard financial reporting period. The company is headquartered in Los Angeles, California, and its common stock is registered on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the procedural aspects of a capital raise.
Material Changes
The material event reported is the filing of a prospectus supplement to the Company's Shelf Registration Statement on Form S-3 (File No. 333-239837). This action registers shares of common stock issuable pursuant to a purchase agreement dated July 8, 2020, with Lincoln Park Capital Fund, LLC.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors. It notes that K&L Gates, LLP, counsel to the Company, has issued a legal opinion relating to the shares issuable under the purchase agreement. No unusual items or contingencies are described in this specific report.
Investor Verification Checklist
- Verify the terms of the purchase agreement dated July 8, 2020, with Lincoln Park Capital Fund, LLC.
- Review the attached legal opinion (Exhibit 5.1) from K&L Gates, LLP regarding the validity of the shares.
- Confirm the number of shares registered in the prospectus supplement to Form S-3.
- Check subsequent filings for the actual closing of the transaction and proceeds received.